LUND, Sweden, Oct. 22, 2020 /PRNewswire/ -- Alligator
Bioscience (Nasdaq Stockholm: ATORX) today announced the
decision to focus its resources on the two proprietary candidate
drugs, ATOR-1017 and mitazalimab. Positive safety and strong Proof
of Mechanism data support moving both into clinical efficacy (Phase
Ib/II) studies in 2021. Due to this prioritization, Alligator will
complete the ongoing dose-escalation study with the bispecific
ATOR-1015 as planned during Q4 2020, after which it will be
partnered for further development.
"ATOR-1017 and mitazalimab are frontrunners worldwide and
Alligator must prioritize and focus investments on these assets to
maximize their value. They both have potential in large cancer
indications with high medical need and billion-dollar markets. They
also target important immune mechanisms where clinical validation
is now emerging and has attracted significant interest already.
Under the revised plan, resources will be concentrated to the
upcoming phase Ib/II efficacy studies for ATOR-1017 and
mitazalimab", said Per Norlén, CEO at Alligator Bioscience.
The decision to focus the clinical resources to ATOR-1017 and
mitazalimab is further explored in the Q3 interim report, published
today October 22 at 8:00 a.m.
Alligator will host a conference call today at 2:00 p.m. CEST for investors, analysts and media,
where CEO Per Norlén will present
and comment on the Q3 interim report and the focus of the clinical
operations. The conference will be held in English. All necessary
information to listen-in and ask questions are available on the
following link: https://financialhearings.com/event/12459
For further information, please contact:
Cecilia Hofvander
Director Investor Relations & Communications
Phone +46 46 540 82 06
E-mail: cecilia.hofvander@alligatorbioscience.com
This information is such information as Alligator Bioscience
AB (publ) is obliged to make public pursuant to the EU Market Abuse
Regulation. The information was submitted for publication, through
the agency of the contact person set out above, at 7:00
a.m. CEST on October 22,
2020.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology
company developing tumor-directed immuno-oncology antibody drugs.
Alligator's pipeline includes the two key assets ATOR-1017 and
mitazalimab. Furthermore, there are two partnered assets;
ALG.APV-527 in co-development with Aptevo Therapeutics Inc. and
AC101 in clinical development by Shanghai Henlius Biotech Inc.). In
addition, the company has developed a novel concept for more
patient-specific immuno-therapy: Neo-X-Prime. Alligator's shares
are listed on Nasdaq Stockholm (ATORX). The Company is
headquartered in Lund, Sweden. For
more information, please visit www.alligatorbioscience.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/alligator-bioscience/r/alligator-bioscience-focuses-on-ator-1017-and-mitazalimab,c3220454
The following files are available for download:
https://mb.cision.com/Main/12681/3220454/1322214.pdf
|
Alligator Bioscience
focuses on ATOR-1017 and mitazalimab
|
View original
content:http://www.prnewswire.com/news-releases/alligator-bioscience-focuses-on-ator-1017-and-mitazalimab-301157659.html
SOURCE Alligator Bioscience